Notice of Half Year Results
Updated : 07:07
17 December 2020
ACCROL GROUP HOLDINGS PLC
("Accrol", the "Company" or the "Group")
AIM: ACRL
NOTICE OF HALF YEAR RESULTS
Accrol Group, one of the UK's leading independent tissue converters, announces that it will release its Half Year Results for the six months to 31 October 2020 on Tuesday, 12 January 2021.
An analyst briefing will be held online at 9.00 am on that day. Equity analysts interested in joining the meeting should contact Belvedere Communications, see contact details below.
A webinar presentation for retail investors will also be held as part of the results roadshow. Details of this event will be announced in due course.
For further information, please contact: |
|
|
|
Accrol Group Holdings plc |
|
Dan Wright, Executive Chairman | Via Belvedere Communications |
Gareth Jenkins, Chief Executive Officer |
|
|
|
Zeus Capital Limited (Nominated Adviser & Broker) |
|
Dan Bate / Jordan Warburton | Tel: +44 (0) 161 831 1512 |
Dominic King / John Goold | Tel: +44 (0) 203 829 5000 |
|
|
Liberum Capital Limited (Joint Broker) | Tel: +44 (0) 20 3100 2222 |
Clayton Bush / Edward Thomas |
|
|
|
Belvedere Communications Limited |
|
Cat Valentine | Tel: +44 (0) 7715 769 078 |
Keeley Clarke | Tel: +44 (0) 7967 816 525 |
Llew Angus | Tel: +44 (0) 7407 023 147 |
| accrolpr@belvederepr.com |
Overview of Accrol
Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls and facial tissues to many of the UK's leading discounters and grocery retailers across the UK. Following the recent acquisition of a state-of-the-art tissue converter based in Leicester, the Group now operates from five sites, including four in Lancashire, which generate revenues totalling c.16% of the £1.7bn UK retail tissue market.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.